ISAL 2019 | Transcription factor alterations in AML and risk: RUNX, CEPBA & EVI1
Ruud Delwel, PhD, of the Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands, discusses transcription factor alterations in acute myeloid leukemia (AML), and how these affect disease risk and response to treatment. Dr Delwel covers RUNX1, C/EBPα, and EVI1, which is a key focus of his lab. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up